Hepatitis C virus recombinants are rare even among intravenous drug users

Journal of Medical Virology

Volumn 82, Issue 2, 2010, Pages 232-238

  Viazov, Sergei ^a   Ross, Stefan S ^a   Kyuregyan, Karen K ^b   Timm, Joerg ^a   Neumann Haefelin, Christoph ^c   Isaeva, Olga V ^b   Popova, Oksana E ^b   Dmitriev, Petr N ^b   Sharkawi, Fathia El ^d   Thimme, Robert ^c   Michailov, Michail I ^b   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c UNIVERSITY OF FREIBURG   (Germany)

^d HELWAN UNIVERSITY   (Egypt)

Author keywords

HCV; HCV genotypes; HCV serotypes; IVDU; Mixed infection

Indexed keywords

NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 4 ANTIBODY; NONSTRUCTURAL PROTEIN 5B; PRIMER RNA; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; FEMALE; GENE SEQUENCE; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUSSIAN FEDERATION; SEROTYPING; VIRUS CORE; VIRUS IDENTIFICATION; VIRUS RECOMBINANT;

ADOLESCENT; ADULT; ANIMALS; BASE SEQUENCE; DRUG USERS; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHENOTYPE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; RUSSIA; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; SEROTYPING; SERUM; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

HEPATITIS C VIRUS; MUREX;

EID: 74549162118     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21631     Document Type: Article

References (37)

1. Aitken CK, Tracy SL, Revill P, Bharadwaj M, Bowden DS, Winter RJ, Hellard ME. 2008. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. J Clin Virol 41:293-296.
2. Bernardin F, Herring B, Page-Shafer K, Kuiken C, Delwart E. 2006. Absence of HCV viral recombination following superinfection. J Viral Hepat 13:532-537.
3. Colina R, Casane D, Vasquez S, Garcia-Aguirre L, Chunga A, Romero H, Khan B, Christina J. 2004. Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 85:31-37.
4. Esteban JI, Sauleda S, Quer J, Hepatol J. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148-162.
5. Gao F, Nainan OV, Khudyakov Y, Li J, Hong Y, Gonzales AC, Spelbring J, Margolis HS. 2007. Recombinant hepatitis C virus in experimentally infected chimpanzees. J Gen Virol 88:143-147.
6. Gates AT, Sarisky RT, Gu B. 2004. Sequence requirements for the development of a chimeric HCV replicon system. Virus Res 100:213-222.
7. Giannini C, Giannelli F, Monti M, Careccia G, Marrocchi ME, Laffi G, Gentilini P, Zignego AL. 1999. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med 134:68-73.
8. Giugliano S, Oezkan F, Bedrejowski M, Kudla M, Reiser M, Viazov S, Scherbaum N, Roggendorf M, Timm J. 2009. Degree of crossgenotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. Hepatology 50:707-716.
9. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. 2004. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 190:1396-1403.
10. Kageyama S, Agdamag DM, Alesna ET, Leona PS, Heredia AM, Abellanosa-Tacan IP, Jerezema LD, Tanimoto T, Yamamura J. 2006. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J Med Virol 78:1423-1428.
11. Kalinina O, Norder H, Mukomolov S, Magnius LO. 2002. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76:4034-4043.
12. Kurbanov F, Tanaka Y, Avazova D, Khan A, Sugauchi F, Kan N, Kurbanova-Khudayberganova D, Khikmatullaeva A, Musabaev E, Mizokami M. 2008a. Detection of hepatitis C virus natural recombinant RF1-2k/1b strain among intravenous drug users in Uzbekistan. Hepatol Res 38:457-464.
13. Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M. 2008b. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1-2k/1b. J Infect Dis 198:1448-1456.
14. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
15. Legrand-Abravanel F, Claudinon J, Nicot F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Pasquier C, Izopet J. 2007. A new natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol 81:4357-4362.
16. Li H, Thomassen LV, Majid A, McMahon BJ, Bruden D, McArdle S, Bano N, Chung M, Carithers RL, Perkins JD, Sullivan DG, Gretch DR. 2008. Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes. J Virol 82:7524-7532.
17. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. 2009. Tight junction proteins claudin-1 and occluding control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83:2011-2014.
18. Ludmerer SW, Graham DJ, Boots E, MurrayEM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL. 2005. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49:2059-2069.
19. Middleton T, He Y, Pilot-Matias T, Trupathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A. 2007. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 145:137-145.
20. Moreau I, Hegarty S, Levis J, Sheehy P, Crosbie O, Kenny-Walsh E, Fanning LJ. 2006. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol J 3:95.
21. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. 2007. Use of sequence analysis of the NS5B region for routine genotyping of hepatitisCviruswith reference to C/E1 and 50 untranslated region sequences. J Clin Microbiol 45:1102-1112.
22. Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD, Haagmans BL. 2006. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol 80:7569-7577.
23. Oniangue-Ndza C, aus dem Siepen M, Lohmann V, Wiese M, Viazov S, Roggendorf M. 2009. Full-length, genomic replicon on the basis of HCV 1b AD78 strain that caused a single-source outbreak of hepatitis C. Virus Res 142:1-9.
24. Proust B, Dubois F, Bacq Y, Le Pogam S, Rogez S, Levillain R, Goudeau A. 2000. Two successive hepatitis C virus infections in an intravenous drug addict. J Clin Microbiol 38:3125-3127.
25. Ross RS, Viazov S, Renzing-Köhler K, Roggendorf M. 2000. Changes in the epidemiology of hepatitis C infection in Germany: Shift in the predominance of hepatitis C subtypes. J Med Virol 60:122-125.
26. Ross RS, Verbeeck J, Viazov S, Lemey P, Van Ranst M, Roggendorf M. 2008.Evidence for a complex mosaic genome pattern in a full-length hepatitis C virus. Evol Bioinformatics 4:249-254.
27. Scherbaum N, Specka M, Bombeck J, Marrziniak B. 2009. Drug consumption facility as part of a primary health care centre for problem drug users - Which clients are attracted? Int JDrug Policy 20:497-499.
28. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
29. Sugitomo K, Kaplan DE, Ikeda F, Ding J, Schwartz J, Nunez FA, Alter HJ, Chang KM. 2005. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol 79:6976-6983.
30. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebtrau A, Miller JL, Manns MP, Rehermann B. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature 6:578-582.
31. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimägi L, Magnius LO. 2007. Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time. J Med Virol 79:374-382.
32. Trupathi RL, Krishnan P, HeY, Middleton T, Pilot-Matias T, Chen CM, Lau DTY, Lemon SM, Mo H, Kati W, Molla A. 2007. Replication efficiency of chimeric replicon containing NS5A-NS5B genes derived from HCV-infected patient sera. Antiviral Res 73:40-49.
33. Tscherne DM, Evans MJ, van Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. 2007. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 81:3693-3703.
34. Viazov S, Kuzin S, Paladi N, Tchernovetsky M, Isaeva E, Mazhul L, Vasychova F, Widell A, Roggendorf M. 1997. Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Moldova, and Uzbekistan). J Med Virol 53:36-40.
35. Viazov S, Widell A, Nordenfelt E. 2000. Mixed infection with two types of hepatitis C virus is probably a rare event. Infection 28:21-25.
36. Worobey M, Holmes EC. 2001. Homologous recombination in GB virus C/hepatitis G virus. Mol Biol Evol 18:254-261.
37. Yun Z, Lara C, Johansson B, de Rivera IL, Sönnerborg A. 1996. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 49:155-160.